PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Dongkyu Kim

Yonsei University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · JOURNAL ARTICLE

Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea

Hepatology International

Real-world retrospective comparison showing lenvatinib superior to sorafenib on OS and treatment durability after first-line immunotherapy in HCC, but observational design and potential confounding limit strength of evidence.

PromisingCholangiocarcinoma and Gallbladder Cancer Studies J. K. Shim Dongkyu Kim

Reported

Sample size295

Lenvatinib arm132

Sorafenib arm163

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support